Understanding the Class Action Lawsuit Against Capricor Therapeutics
Investors in Capricor Therapeutics, Inc. are facing potential implications due to a class action securities lawsuit initiated by Levi & Korsinsky, LLP. This firm is alerting shareholders regarding their rights and the actions they may take. It's crucial for stakeholders to stay informed about these proceedings and the implications for their investments.
Details of the Class Action
The class action lawsuit seeks to recover losses for investors who experienced adverse effects related to allegations of securities fraud involving the company. Notably, the investigation pertains to events that unfolded between specific dates, highlighting serious allegations against the firm.
Significant Allegations Against Capricor
According to the legal complaint, Capricor's management made misleading statements about its lead drug candidate, deramiocel, which is under review for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The lawsuit alleges that the company misrepresented its progress in obtaining a Biologics License Application (BLA) from the FDA, while simultaneously failing to disclose significant negative information regarding clinical safety and effectiveness data.
Consequences for Investors
Following a press release from Capricor on July 11, 2025, announcing a Complete Response Letter (CRL) from the FDA, the stock price took a notable hit, falling dramatically within a day. This decline stressed the potential risks posed to investors who had invested based on prior public statements that lacked necessary disclosures.
Your Rights as an Investor
For those who experienced losses, there are options to act, including the decision to request to be appointed as the lead plaintiff in the ongoing lawsuit. However, it’s vital to note that there's no requirement for investors to participate as lead plaintiffs in order to seek recovery. Interested parties can find further information from legal teams in this area.
No Out-of-Pocket Costs
Investors should be assured that participation in the lawsuit has no associated out-of-pocket costs. Class members could potentially recover funds without any initial financial obligations. This guidance is essential for stakeholders aiming to navigate the complexities of this legal situation.
Levi & Korsinsky’s Track Record
Over the past two decades, Levi & Korsinsky has built a strong reputation, securing substantial compensation for shareholders and developing a history of winning complex cases. The firm is staffed by a dedicated team focused on representing investors in various securities litigation matters.
Contact Information
For more information, investors can reach out to Levi & Korsinsky, LLP. The firm is available for inquiries, and interested shareholders can contact Joseph E. Levi at (212) 363-7500 or via email.
Frequently Asked Questions
What is the purpose of the class action lawsuit against Capricor Therapeutics?
The lawsuit aims to recover losses for investors who may have been misled by the company's statements relating to its lead drug candidate, deramiocel.
How can I participate in the lawsuit?
Investors can request to be appointed as a lead plaintiff or simply participate in the recovery process without leading the case.
Are there any costs associated with joining the lawsuit?
No, participation in the class action is free of charge to class members.
What information do I need to provide to join the class action?
Interested investors should provide relevant details about their shareholdings and any losses incurred during the specified time frame.
Who can I contact for more information about the lawsuit?
Investors can contact Levi & Korsinsky, LLP for more details about their rights and potential actions regarding the lawsuit against Capricor Therapeutics, Inc.
